Clinical outcomes by arms
| . | Arm 1, n = 66 . | Arm 2, n = 64 . | P . |
|---|---|---|---|
| Hematopoietic recovery, median (range), d | |||
| ANC engraftment | 19 (11-53) | 20 (12-89) | .76 |
| Platelet engraftment | 31 (16-83) | 31 (12-87) | .66 |
| Transplant outcomes, % (95% CI) | |||
| OS | 64 (51-75) | 67 (53-77) | .92 |
| RFS | 52 (38-64) | 62 (49-73) | .39 |
| TRM | 16 (8-26) | 21 (12-31) | .67 |
| Relapse | 31 (19-43) | 17 (9-27) | .16 |
| aGVHD II-IV | 54 (41-66) | 57 (44-68) | .49 |
| aGVHD III-IV | 10 (5-15) | 10 (5-15) | .91 |
| . | Arm 1, n = 66 . | Arm 2, n = 64 . | P . |
|---|---|---|---|
| Hematopoietic recovery, median (range), d | |||
| ANC engraftment | 19 (11-53) | 20 (12-89) | .76 |
| Platelet engraftment | 31 (16-83) | 31 (12-87) | .66 |
| Transplant outcomes, % (95% CI) | |||
| OS | 64 (51-75) | 67 (53-77) | .92 |
| RFS | 52 (38-64) | 62 (49-73) | .39 |
| TRM | 16 (8-26) | 21 (12-31) | .67 |
| Relapse | 31 (19-43) | 17 (9-27) | .16 |
| aGVHD II-IV | 54 (41-66) | 57 (44-68) | .49 |
| aGVHD III-IV | 10 (5-15) | 10 (5-15) | .91 |